Bioasis Technologies

Bioasis Technologies ROCE

The Return on Capital Employed (ROCE) of Bioasis Technologies (BIOAF) as of Oct 19, 2026 is 187.59 %. In the previous year, Return on Capital Employed (ROCE) was 93.34 % — a change of 100.96% (higher).

ROCE

187.59 %

YoY

100.96%

Last updated:

In 2022, Bioasis Technologies's return on capital employed (ROCE) was 187.59 %, a 100.96% increase from the 93.34 % ROCE in the previous year.

The Bioasis Technologies ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2015
-142.00 CAD
Jan 1, 2016
-149.13 CAD
Jan 1, 2017
-821.63 CAD
Jan 1, 2018
-1,215.69 CAD
Jan 1, 2019
888.62 CAD
Jan 1, 2020
185.08 CAD
Jan 1, 2021
93.34 CAD
Jan 1, 2022
187.59 CAD
The Bioasis Technologies ROCE history
YEARROCEYoY
187.59 %+100.96%
93.34 %-49.57%
185.08 %-79.17%
888.62 %-173.10%
-1,215.69 %+47.96%
-821.63 %+450.95%
-149.13 %+5.02%
-142.00 %-6.76%
-152.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bioasis Technologies Stock analysis

What does Bioasis Technologies do? Bioasis Technologies Inc, trading under the ticker symbol BIOAF and identified by ISIN CA09064N1033, is a biopharmaceutical enterprise headquartered in Burnaby, British Columbia, Canada. The company entered the public markets on July 24, 2007, establishing its presence in the health care sector, specifically within the biotechnology industry. Bioasis Technologies is primarily focused on the research and development of innovative therapeutic solutions for central nervous system disorders, addressing areas characterized by significant unmet medical needs. The firm’s core scientific strategy revolves around the development of the xB3 platform, a proprietary technology designed to facilitate the delivery of therapeutics across the blood-brain barrier. This biological hurdle has long been a major challenge in treating brain-related diseases, as most conventional drugs are unable to penetrate this protective layer in sufficient quantities to be effective. The xB3 platform leverages a human transport protein that circulates at low levels in the blood to achieve its therapeutic goals. By utilizing a biological mechanism known as receptor-mediated transcytosis, the platform is engineered to shuttle therapeutic molecules across the blood-brain barrier and deliver them directly to their intended targets within the brain. This approach holds promise for improving treatment outcomes in complex conditions such as brain cancers and neurodegenerative diseases. The company’s in-house development programs are structured to create both symptomatic relief and disease-modifying treatments for a variety of disorders affecting the central nervous system. Bioasis Technologies continues to operate from its Burnaby headquarters, leveraging its specialized platform to advance its pipeline of potential treatments. The company’s website, accessible at https://www.bioasis.us/, serves as a resource for information regarding its ongoing scientific initiatives and corporate developments. As a publicly traded entity, Bioasis Technologies remains committed to advancing the frontiers of biotechnology in the fight against some of the most challenging neurological conditions, relying on its unique xB3 technology to bridge the gap between systemic administration and effective central nervous system intervention. Bioasis Technologies is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Bioasis Technologies's Return on Capital Employed (ROCE)

Bioasis Technologies's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Bioasis Technologies's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Bioasis Technologies's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Bioasis Technologies’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Bioasis Technologies stock

Return on Capital Employed (ROCE) of Bioasis Technologies is 187.59 % in 2022.

Return on Capital Employed (ROCE) of Bioasis Technologies changed from 93.34 % to 187.59 %, representing a 100.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Bioasis Technologies since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Bioasis Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Bioasis Technologies

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Bioasis Technologies